The Pharma Data

MAY 18, 2021

Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needs. Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls, Spain expands for sterile active pharmaceutical ingredients.

Manufacturing 40

Manufacturing Production Containment Generic Pharmaceutical 40

The Pharma Data

JUNE 17, 2022

With a strong portfolio of eight marketed biosimilars and a further 15+ in various stages of development, Sandoz has an unparalleled heritage and extensive expertise in the development, manufacturing and delivery of biosimilar medicines to patients and the healthcare community worldwide.

Medicine 52

Medicine Generic Pharmaceutical FDA Approval Packaging 52

Pharma in Brief

DECEMBER 3, 2023

The listed patents must be addressed by the manufacturer of a generic or biosimilar drug before its drug can receive a Notice of Compliance ( NOC ) and be sold in Canada. The early-working exception allows generic or biosimilar manufacturers to work a patented invention “for uses reasonably related” to obtaining regulatory approval.

Regulation 52

Regulation Compliance Medicine Manufacturing 52

The Pharma Data

MAY 8, 2021

Eylea ® is a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc. This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.

Clinical Development 52

Clinical Development Medicine Development Containment 52

The Pharma Data

MAY 2, 2021

Eylea ® is a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc. This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.

Clinical Development 40

Clinical Development Medicine Development Production 40

The Pharma Data

MAY 15, 2023

For more information on the Sandoz Board of Directors, please also see [link] Disclaimer This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Our ambition is to be the world’s leading and most valued generics company.

Sales 40

Sales Production Doctors Doctor 40

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. It contains the antiviral medications nirmatrelvir and ritonavir. billion the drug generated in 2021. billion in 2022, a 23.43 Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98